Bodhi Tree Biotechnology Reports Critical Liquidity, Material Control Weaknesses, and Extreme Customer Concentration

summarizeSummary

Bodhi Tree Biotechnology reported a critically low cash balance, material weaknesses in internal controls, and 100% revenue concentration from a single customer, highlighting significant going concern risks.

check_boxKey Events

• Severe Cash Depletion

  Cash balance decreased significantly to $22,750 as of March 31, 2026, down from $109,404 six months prior, indicating a rapid cash burn.

• Material Weaknesses in Internal Controls

  Management concluded that disclosure controls were ineffective due to material weaknesses in internal control over financial reporting, citing a lack of US GAAP knowledge and segregation of duties.

• Extreme Revenue Concentration

  100% of the company's revenue for the six months ended March 31, 2026, was derived from a single individual customer, posing a critical business risk.

• Reliance on Future Funding

  The company explicitly states its plan to fund operations through public offerings or private placements, underscoring a significant going concern risk.

auto_awesomeAnalysis

This quarterly report reveals Bodhi Tree Biotechnology is in a highly precarious financial state. The cash balance has plummeted to a critically low $22,750, and the company explicitly states its dependence on future public or private funding to continue operations. This severe liquidity crunch, combined with the disclosure of material weaknesses in internal controls (specifically, a lack of US GAAP knowledge and proper segregation of duties), raises serious concerns about the company's financial reliability and governance. Furthermore, the business faces extreme concentration risk, with all revenue for the past six months derived from a single customer. While the company achieved an OTCQB listing, this positive development is heavily overshadowed by these fundamental financial and operational challenges.